In the present review, we explore the recent progress of COX-2 molecular imaging in CRC, by comparing the radioligands' characteristics and highlighting the obstacles that remain to be overcome in order to achieve the clinical development of such a radiotracer. This evidence concerns the gene PTGS2 and colorectal carcinoma.